Post Mastectomy Reconstruction denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for post mastectomy reconstruction are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Post-Mastectomy Reconstruction as Duplicate Therapy

A duplicate-therapy denial means the insurer's system flagged that a service or procedure it considers equivalent to something already approved or performed has been requested again. For post-mastectomy breast reconstruction, this sometimes arises when a multi-stage reconstruction plan — for example, tissue expander placement followed by implant exchange, or staged flap revision — is misread by the claims system as a repeat of an already-completed procedure rather than as a planned, distinct surgical phase.

This denial type is nearly always administrative in origin. The Women's Health and Cancer Rights Act (WHCRA) of 1998 is a federal law that requires group health plans covering mastectomy to also cover all stages of reconstruction on the affected breast, reconstruction of the other breast to achieve symmetry, prostheses, and treatment of physical complications. A blanket duplicate-therapy denial cannot override this statutory obligation.

## Why It Is Appealable

Because WHCRA applies to most employer-sponsored and individual plans, and because reconstruction is frequently a multi-stage, clinically sequenced process rather than a single event, a duplicate-therapy label is almost always an error in clinical context. Your appeal should demonstrate that the requested procedure is a distinct, medically necessary stage of a documented reconstruction plan — not a repetition of a previously completed service.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full-and-fair internal review. Submit within the timeframe on your denial notice (typically 180 days for non-grandfathered plans).
• External review (ACA §2719): After exhausting internal appeal, you may request independent external review. The standard window is approximately four months from the final internal denial.
• Expedited review: Available when your health would be seriously jeopardized by waiting for standard review. Request it in writing simultaneously with your internal appeal if timing is urgent.

## Concrete Appeal Steps and Timeline

1. Request the complete denial letter and your insurer's internal criteria document for reconstruction coverage. 2. Obtain a detailed operative report and treatment plan from your surgical team clearly describing each stage as a discrete, planned phase. 3. Submit your internal appeal packet within the deadline on the denial notice. 4. If denied internally, file for external review promptly.

## Documentation to Gather

• Diagnosis and surgical history: Pathology report, mastectomy operative note, and records confirming the cancer diagnosis.
• Reconstruction treatment plan: A written plan from your plastic surgeon identifying each stage, the clinical rationale for staging, and why this visit represents a new phase rather than a repeat.
• Prior authorization records: Any prior-auth approvals for earlier stages, demonstrating that BCBS itself recognized the multi-stage nature of the plan.
• Prescriber medical-necessity letter: A letter from your surgeon explaining, in plain terms, why this stage is distinct from any prior approved procedure.
• WHCRA citation: Reference the federal statute directly in your appeal letter.

## Criteria-Mapping Structure

Copy each coverage requirement from BCBS's published medical/coverage policy for breast reconstruction. For each requirement, document the specific chart fact that satisfies it. Explicitly note the stage number, the date of the prior stage, and the clinical reason the current stage is not duplicative. This one-to-one mapping is the most persuasive format for both internal and external reviewers.